199 related articles for article (PubMed ID: 22335611)
1. Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies.
Coppola A; Franchini M; Makris M; Santagostino E; Di Minno G; Mannucci PM
Haemophilia; 2012 May; 18(3):e173-87. PubMed ID: 22335611
[TBL] [Abstract][Full Text] [Related]
2. Non-thrombotic-, non-inhibitor-associated adverse reactions to coagulation factor concentrates for treatment of patients with hemophilia and von Willebrand's disease: a systematic review of prospective studies.
Franchini M; Makris M; Santagostino E; Coppola A; Mannucci PM
Haemophilia; 2012 May; 18(3):e164-72. PubMed ID: 22250981
[TBL] [Abstract][Full Text] [Related]
3. No inhibitor development after continuous infusion of factor concentrates in subjects with bleeding disorders undergoing surgery: a prospective study.
Auerswald G; Bade A; Haubold K; Overberg D; Masurat S; Moorthi C
Haemophilia; 2013 May; 19(3):438-44. PubMed ID: 23279056
[TBL] [Abstract][Full Text] [Related]
4. Clinical uses of plasma and plasma fractions: plasma-derived products for hemophilias A and B, and for von Willebrand disease.
Josephson CD; Abshire TC
Best Pract Res Clin Haematol; 2006; 19(1):35-49. PubMed ID: 16377540
[TBL] [Abstract][Full Text] [Related]
5. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events.
Ehrlich HJ; Henzl MJ; Gomperts ED
Haemophilia; 2002 Mar; 8(2):83-90. PubMed ID: 11952842
[TBL] [Abstract][Full Text] [Related]
6. Treatment of haemophilia A and B and von Willebrand's disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment.
Berntorp E; Astermark J; Baghaei F; Bergqvist D; Holmström M; Ljungberg B; Norlund A; Palmblad J; Petrini P; Stigendal L; Säwe J
Haemophilia; 2012 Mar; 18(2):158-65. PubMed ID: 22151198
[TBL] [Abstract][Full Text] [Related]
7. Central venous access devices for paediatric patients with haemophilia: a single-institution experience.
Titapiwatanakun R; Moir C; Pruthi RK; Stavlo PL; Schmidt KA; Rodriguez V
Haemophilia; 2009 Jan; 15(1):168-74. PubMed ID: 19149849
[TBL] [Abstract][Full Text] [Related]
8. [Haemophilia A, B or von Willebrand disease type 3. Census of patients in the eastern part of Germany].
Scholz U; Syrbe G; Koscielny J; Klamroth R;
Hamostaseologie; 2008; 28(3):150-4. PubMed ID: 18521493
[TBL] [Abstract][Full Text] [Related]
9. Von Willebrand disease within the collective of haemophilic patients as reason for unexpected bleeding episodes.
Siegmund B; Richter H; Pollmann H
Haemophilia; 2007 Jan; 13(1):21-5. PubMed ID: 17212720
[TBL] [Abstract][Full Text] [Related]
10. Safety surveillance in haemophilia and allied disorders.
Lassila R; Makris M
J Intern Med; 2016 Jun; 279(6):515-23. PubMed ID: 27001233
[TBL] [Abstract][Full Text] [Related]
11. Current therapy for rare factor deficiencies.
Di Paola J; Nugent D; Young G
Haemophilia; 2001 Jan; 7 Suppl 1():16-22. PubMed ID: 11240614
[TBL] [Abstract][Full Text] [Related]
12. The safety of pharmacologic options for the treatment of persons with hemophilia.
Franchini M; Mannucci PM
Expert Opin Drug Saf; 2016 Oct; 15(10):1391-400. PubMed ID: 27367551
[TBL] [Abstract][Full Text] [Related]
13. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
[TBL] [Abstract][Full Text] [Related]
14. Clinical use of Haemate® P in von Willebrand disease: a 25-year retrospective observational study.
Miesbach W; Krekeler S; Wolf Z; Seifried E
Thromb Res; 2015 Mar; 135(3):479-84. PubMed ID: 25595881
[TBL] [Abstract][Full Text] [Related]
15. Emergency department care for patients with hemophilia and von Willebrand disease.
Singleton T; Kruse-Jarres R; Leissinger C
J Emerg Med; 2010 Aug; 39(2):158-65. PubMed ID: 18757163
[TBL] [Abstract][Full Text] [Related]
16. Clotting factor concentrate use and occurrence of thrombotic events in patients with hemophilia: A nationwide and 15-year cohort study.
Tsan YT; Wang JD; Chan WC; Tong KM
Am J Hematol; 2016 Jun; 91(6):E307-8. PubMed ID: 26972918
[No Abstract] [Full Text] [Related]
17. A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.
Berntorp E; Archey W; Auerswald G; Federici AB; Franchini M; Knaub S; Kreuz W; Lethagen S; Mannucci PM; Pollmann H; Scharrer I; Hoots K
Eur J Haematol Suppl; 2008 May; (70):3-35. PubMed ID: 18380871
[TBL] [Abstract][Full Text] [Related]
18. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
19. Outcomes in Patients With Hemophilia and von Willebrand Disease Undergoing Invasive or Surgical Procedures.
Chapin J; Bamme J; Hsu F; Christos P; DeSancho M
Clin Appl Thromb Hemost; 2017 Mar; 23(2):148-154. PubMed ID: 27418638
[TBL] [Abstract][Full Text] [Related]
20. Progress in the treatment of bleeding disorders.
Bergman GE
Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
